Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
Hideaki Katagiri,1 Masanori Taketsuna,2 Shinpei Kondo,3 Kenta Kajimoto,4 Etsuko Aoi,5 Yuka Tanji1 1Bio Medicine, 2Statistical Sciences, 3Post Marketing Study Management, 4Scientific Communications, Medicines Development Unit Japan, 5Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly...
Main Authors: | Katagiri H, Taketsuna M, Kondo S, Kajimoto K, Aoi E, Tanji Y |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-01-01
|
Series: | Neuropsychiatric Disease and Treatment |
Subjects: | |
Online Access: | https://www.dovepress.com/safety-and-effectiveness-of-rapid-acting-intramuscular-olanzapine-for--peer-reviewed-article-NDT |
Similar Items
-
A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
by: Katagiri Hideaki, et al.
Published: (2013-01-01) -
Evaluation of intramuscular olanzapine and ziprasidone in the medically ill
by: Seema M. Patel, PharmD, BCPP, et al.
Published: (2021-01-01) -
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial
by: Charles Lung-Cheng Huang, et al.
Published: (2015-05-01) -
Evaluation of the use of chlorpromazine for agitation in pediatric patients
by: Rajwoana Ahmed, PharmD, et al.
Published: (2023-03-01) -
The Psychopharmacology of Agitation: Consensus Statement of the American Association for Emergency Psychiatry Project BETA Psychopharmacology Workgroup
by: Michael P. Wilson, et al.
Published: (2012-04-01)